NCT07807839 Study of Correlation Between Serum BDNF Levels and Pfirmann Grading and IL- 1β
| NCT ID | NCT07807839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Keimyung University Dongsan Medical Center |
| Condition | Chronic Low Back Pain (CLBP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 59 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 59 participants in total. It began in 2026-09-01 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Brain-derived neurotrophic factor (BDNF) is a protein belonging to the neurotrophin family, known to be involved in neuronal survival, growth, and synaptic plasticity. Recent studies suggest that the role of BDNF may extend beyond the central nervous system to include inflammatory responses and degenerative changes in peripheral tissues. In particular, BDNF expression has been confirmed within intervertebral disc tissue, with degenerated discs showing increased BDNF expression compared to normal discs, and this expression has been reported to increase further with the severity of degeneration Intervertebral disc degeneration is closely associated with intradiscal nerve ingrowth (neoinnervation) and the resulting generation of pain, and BDNF has been reported as a factor mediating this nerve ingrowth and pain sensitization (central/peripheral sensitization) within the disc. Interleukin-1 beta (IL-1β), a representative inflammatory cytokine of disc degeneration, is known as a key mediator that promotes extracellular matrix degradation within disc tissue and induces neoinnervation and sensitization. Because BDNF secretion from neurons and immune cells has also been reported to increase in inflammatory environments, a potential interaction between IL-1β and BDNF has been proposed Accordingly, this study aims to measure serum BDNF concentrations in patients presenting with low back and leg pain due to disc degeneration or spinal stenosis, and to analyze whether these levels show a consistent correlation with Pfirrmann grading on MRI and serum IL-1β concentration.
Eligibility Criteria
Inclusion Criteria: * lumbar disc herniation * lumbar spinal canal stenosis * patients who have MRI Exclusion Criteria: * spine fracture * spine infection * spine tumor * rhematoid arthritis * ankylosing spondylitis * systemic lupus erythematosus * peripheral neuropathy * fibromyalgia * patient taking antidepressant, antipsychotics, acetylcholiesterase inhibitor
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07807839 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Chronic Low Back Pain (CLBP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07807839 currently recruiting?
Yes, NCT07807839 is actively recruiting participants. Contact the research team at swon13@daum.net for enrollment information.
Where is the NCT07807839 trial being conducted?
This trial is being conducted at Daegu, South Korea.
Who is sponsoring the NCT07807839 clinical trial?
NCT07807839 is sponsored by Keimyung University Dongsan Medical Center. The trial plans to enroll 59 participants.